Skip to main content
See every side of every news story
Published loading...Updated

NHS ‘worst in Europe’ for paying for drugs, says Mounjaro maker

Eli Lilly's CEO warns UK pricing and rebate policies deter investment and new medicines, with nearly 23% NHS rebate cited as a key challenge, risking patient access to treatments.

  • Dave Ricks, chief executive of Eli Lilly and Company, told the Financial Times the UK is the least attractive market in Europe and warned companies may withhold new medicines and investment unless pricing rules change.
  • Amid rising rebate levels, Ricks highlighted the VPAG clawback, which he described as punishing success and should be removed.
  • Industry figures show drug companies have suspended or cancelled almost 1.8 billion of UK investment this year, with four major projects worth over 1.8 billion abandoned.
  • Lilly sharply raised Mounjaro's private price by up to 170 per cent last month amid cross-border buying, and Ricks warned UK patients could miss treatments while legal action looms.
  • The UK government earlier this month said more work is needed to change the life sciences landscape, with investments of up to 600m and 520m supporting an estimated 100bn sector and over 300,000 jobs.
Insights by Ground AI

7 Articles

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 60% of the sources lean Right
60% Right

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

The Telegraph broke the news in London, United Kingdom on Wednesday, September 24, 2025.
Sources are mostly out of (0)
News
For You
Search
BlindspotLocal